Medixbio Inc

Medix Biotechnologies Inc. develops AI-enabled molecular diagnostic solutions designed to provide laboratory-grade testing accuracy in point-of-care and home settings. At the core of its product ecosystem is Genometriq™, an algorithmic design engine that utilizes advanced computational methods and artificial neural networks to automate the development of highly specific, multiplexed molecular assays. These assays are designed to detect multiple pathogens and antibiotic resistance genes simultaneously, with platforms such as Hypersens™, Ultrasens™, and Rapidmarc™ facilitating rapid testing across various formats, from smartphone-read self-test cards to qPCR kits.

By streamlining the identification of genetic targets and enabling rapid, decentralized testing, Medix aims to address fragmented and inefficient diagnostic pathways. The company's platforms, often complemented by TreatOnce™ clinical decision support software, assist clinicians and researchers by mapping detected pathogens to targeted antimicrobial treatment options. These tools are intended to improve testing efficiency, reduce turnaround times, and support informed treatment decisions in fields including infectious diseases, pharmaceutical R&D, and food safety, with many of its current offerings provided for research use only.